Creon 60000 [USP'U]/1 (Pancrelipase CAPSULE, DELAYED RELEASE PELLETS) 60000 [USP'U]/1

Pancrelipase, the active ingredient in Creon 60000 [USP'U]/1, works by providing exogenous lipase, amylase, and protease enzymes. These enzymes help break down fats, carbohydrates, and proteins in the digestive tract, compensating for the lack of natural pancreatic enzymes in patients with exocrine pancreatic insufficiency. The delayed-release formulation ensures that the enzymes are released in the small intestine, where they are most effective.

The dosage of Creon 60000 [USP'U]/1 is determined by a healthcare provider based on the patient's condition, dietary fat intake, and individual response to the medication. It is typically taken with meals and snacks. The prescriber will adjust the dosage as needed to achieve optimal digestive function.

The safety of Creon 60000 [USP'U]/1 during pregnancy or breastfeeding has not been fully established. Pregnant or breastfeeding women should consult their healthcare provider before using this medication. The healthcare provider will weigh the potential benefits against the risks to determine if the medication is appropriate.

To order Creon 60000 [USP'U]/1 from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping, and the import paperwork.

Creon 60000 [USP'U]/1 is one of the leading pancreatic enzyme replacement therapies available. It is known for its delayed-release formulation, which ensures that the enzymes are released in the small intestine, where they are most effective. Compared to other therapies, Creon is widely prescribed and has a well-established safety and efficacy profile.

Creon 60000 [USP'U]/1 should be stored below 25°C, in the original pack, and protected from moisture. The capsules should be swallowed whole with a glass of water or juice to ensure that the pellets are swallowed. Do not crush, chew, or retain the capsules in the mouth to avoid irritation of the oral mucosa.

Creon 60000 [USP'U]/1 is administered orally with meals or snacks. The capsules should be swallowed whole with a glass of water or juice. For patients who have difficulty swallowing, the capsule can be opened, and the contents can be mixed with a small amount of soft food or liquid. Care should be taken to avoid inhaling the powder.

The most serious risks associated with Creon 60000 [USP'U]/1 include fibrosing colonopathy, gastrointestinal obstruction, and hyperuricemia. Patients should be monitored regularly for signs of these conditions. Any unusual symptoms should be reported to a healthcare provider immediately.

Creon 60000 [USP'U]/1 should not be used by individuals who are allergic to pork proteins or any of the other ingredients in the medication. Patients with certain medical conditions or those taking specific medications should consult their healthcare provider before using Creon to ensure it is safe for them.